Nanomedical Diagnostics Highlights Launch of Graphene Biosensor at Graphene World Summit

Nanomedical Diagnostics, a Serra Capital portfolio company, is set to present at the Graphene World Summit on September 19 and 20. Nanomedical Diagnostics is a biotech company based in San Diego, CA, and is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. 

Dr. Brett Goldsmith, Founder and CTO of Nano, will present a session titled “Graphene: Uniting Biology and Electronics," which will showcase the company's commercialized graphene-based AGILE R100 biosensor.  Dr. Goldsmith shares "Graphene has made it possible to link biology directly with electronics for the first time, bringing an entire world of new capabilities to drug discovery and life science research.”